



# Corporate Presentation Abbreviated

September 2024

NASDAQ: TNXP

Version P0600 September 11, 2024 (Doc 1512)

© 2024 Tonix Pharmaceuticals Holding Corp.



# Cautionary Note on Forward-Looking Statements

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

# Who We Are

Tonix is committed to developing and marketing therapeutics to treat pain, neurologic, psychiatric and addiction conditions through our ***central nervous system portfolio*** and within other areas of ***high unmet need***, including immunology, infectious disease, and rare disease

*With a Focus on:*

***Filing a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for TNX-102 SL for the management of Fibromyalgia***



# Mpox Declared Public Health Emergency of International Concern (PHEIC) by WHO\* on August 14, 2024: New Clade 1

- Clade 1 - first wave in Democratic Republic of Congo (DRC),
  - 10% mortality,
  - Affects children
- Additional emerging mutation,
  - ~0.5% mortality,
  - Affects both MSM (men who have sex with men) + heterosexual transmission primarily in adults
- 2024 mpox epidemic out-of-control in DRC has led to >20,000 cases mid August caught and spread to 12 countries in Africa
- First cases identified in Sweden, Thailand, Singapore and Kenya
- Only one FDA\*\*-approved vaccine:
  - Jynneos® (Bavarian-Nordic) – requires 2 dose regimen, durability of neutralization antibody titers being studied<sup>1,2</sup>
- Another potential mpox vaccine, is FDA approved for smallpox
  - ACAM 2000 (Emergent) – single-dose, reactogenic, provides durable protection
  - Emergency use/expanded access for mpox<sup>3</sup>

\*WHO = World Health Organization

\*\*FDA = U.S. Food and Drug Administration

<sup>1</sup>Zaack LM, *Nat Med*. 2023 29(1):270-278. doi: 10.1038/s41591-022-02090

<sup>2</sup>Berens-Riha N, et al. *Euro Surveill*. 2022 27(48):2200894. doi: 10.2807/1560-7917.ES.2022.27.48.2200894.

<sup>3</sup>ACAM 2000 has expanded access status for use in mpox and an application for full approval is before the U.S. FDA





# Mpox Outbreak 2022-23: Clade 2b

## Public Health Emergency Global Health Concern

### Risk of Spread and Lethality of Clade 2b

- Case Fatality Rate (CFR): 0.1% to 3.6% → Lower compared to Clade 1
- Primarily spread through sexual contact among MSM (men who have sex with men)
- Rapid and significant spread beyond endemic regions → Over 90,000 cases reported in more than 100 countries by the end of 2022
- Systemic symptoms and rash leading to medical interventions in up to 40% of cases



Total Cases: 95,912; 92,982 were in locations that have not historically reported Mpox  
 Total Location: 118; 111 has not historically reported Mpox

Sources: WHO, European CDC, US CDC, and Ministries of Health  
[2022 U.S. Map and Case Count | Mpox | Poxvirus | CDC](#)  
 WHO = World Health Organization  
 FDA = U.S. Food and Drug Administration



# Monkeypox Headlines

- Multiple recent statements by U.S. Agencies warning about smallpox and monkeypox<sup>1-6</sup>
- U.S. National Academy of Sciences Consensus Report (March, 2024)<sup>6</sup>
  - *“Additionally, safer, single-dose vaccines and a diverse set of therapeutic options against smallpox would improve the U.S. readiness and response posture for immediate containment and long-term protection in a smallpox emergency.*
  - *“Smallpox vaccines that have improved safety across different population subgroups and are available as a single dose would support faster and more effective response to contain smallpox and other orthopoxvirus outbreaks. The development of novel smallpox vaccines using multi-vaccine platforms (i.e., use common vaccine vectors, manufacturing ingredients, and processes) would improve the capacity for rapid vaccine production in response to a smallpox event and reduce the need for stockpiling in the SNS at current levels.*
  - *“Given the lack of commercially available orthopoxvirus diagnostics, vaccines, and therapeutics, planning for logistics and supply chain management considerations is critical. Efforts could give consideration to developing plans to increase the number of smallpox vaccine and therapeutics manufacturers as well as optimizing current manufacturing capacities should they be needed in the shorter term.”*

<sup>1</sup> Office of Science and Technology Policy (OSTP). American Pandemic Preparedness: Transforming Our Capabilities. September 2021

<sup>2</sup> National Biodefense Science Board (NBSB). Prioritization of Product Attribute Categories to Maximize Access for Next Generation COVID-19 Vaccines and Therapeutics. August 2023

<sup>3</sup> Office of Science and Technology Policy (OSTP). American Pandemic Preparedness: Transforming Our Capabilities. September 2021

<sup>4</sup> National Biodefense Science Board (NBSB). Prioritization of Product Attribute Categories to Maximize Access for Next Generation COVID-19 Vaccines and Therapeutics. August 2023

<sup>5</sup> BARDA Strategic Plan 2022-2026.

<sup>6</sup> U.S. National Academy of Sciences. March 28, 2024. “Consensus Study Report: Future State of Smallpox Medical Countermeasures.”

<https://nap.nationalacademies.org/catalog/27652/future-state-of-smallpox-medical-countermeasures>

# TNX-801


Live Virus Vaccine

---

*Live virus vaccine platform with multitude of potential applications*

# TNX-801: Recombinant Pox Vaccine (RPV) Platform Using Live Virus Technology

Cloned version of horsepox<sup>1</sup> purified from cell culture



## Key Differentiators

### Live virus vaccines are the most established vaccine technology

- Prevents forward transmission
- Effective in eliciting durable or long-term immunity

### Economical to manufacture at scale

- Low dose because replication amplifies dose *in vivo*
- Single administration

### Standard refrigeration for shipping and storage





## TNX-801: Pre-IND Ready Candidate Mpox Vaccine

- Based on synthetic horsepox-vector, believed related to first smallpox vaccine used by Dr. Edward Jenner in 1796
- Single-dose percutaneous
- Attenuated live virus for durable T-cell immunity similar to 19<sup>th</sup> Century vaccinia
- Believed to be thermo stable in ultimate lyophilized formulation
- Eventual presentation using Micro Array Patch – working with developers



R&D Center- Maryland  
Operational BSL-3 capable




Advanced Manufacturing Center- MA  
GMP-manufacturing capability\*

\*GMP Suites currently decommissioned

# Illustrative Safety Spectrum Of Pox-based Vaccine Vectors

## Optimizing Live Virus Vaccines




Replicative Capacity	Non-replicating	Minimally-replicating			Robustly replicating
#-of doses	Two	Single-dose			Single-dose
Durability of protection	waning	long			decades
Transgene expression	Poor	robust			robust



# TNX-801 Vaccination and Clade 1 Lethal Challenge in Macaques

Vaccination					Challenge		
Group	Vaccine	N	Dose (Log <sub>10</sub> PFU)	Route	Virus	Dose (Log <sub>10</sub> PFU)	Route
1	TNX-801 (High Dose)	4	6.6	Scarification	MPXV (Zaire)	5.0	IT
2	TNX-801 (Low Dose)	4	5.7	Scarification	MPXV (Zaire)	5.0	IT
3	rVACV	4	5.0	Scarification	MPXV (Zaire)	5.0	IT
4	Mock	4	-	Scarification	MPXV (Zaire)	5.0	IT




**“Take” observed in all TNX-801 vaccinated NHPs except one.**

- If no take by day 7 NHPs were revaccinated on day 14.

**Post-vaccination, no NHP showed lesions during first 60 days**




# Immunogenicity: Neutralizing Antibody (PRNT<sub>50</sub> Assay)



88% of TNX-801 vaccinated NHPs had neutralizing antibody responses 8- to 50-fold from baseline



# Clinical Signs (Lesions) After MPXV Challenge




**NHPs vaccinated with TNX-801:  
No lesions observed after MPXV challenge in any of the eight animals**

Noyce RS, et al. *Viruses*. 2023;15(2):356. doi: 10.3390/v15020356.



# Clinical Disease: Lethality




No deaths in the TNX-801 vaccinated groups

Noyce RS, et al. *Viruses*. 2023;15(2):356. doi: 10.3390/v15020356.

# TNX-801: Recombinant Pox Vaccine (RPV) Platform Using Live Virus Technology

Cloned version of horsepox<sup>1</sup> purified from cell culture



## Key Differentiators

### Live virus vaccines are the most established vaccine technology

- Prevents forward transmission
- Effective in eliciting durable or long-term immunity

### Economical to manufacture at scale

- Low dose because replication amplifies dose *in vivo*
- Single administration

### Standard refrigeration for shipping and storage



## TNX-1800\*: Designed to Express the SARs-CoV-2 Spike Protein

TNX-1800 (recombinant horsepox virus) is a live virus vaccine based on Tonix's TNX-801 that is designed to express the spike protein of the SARS-CoV-2 virus and to elicit a predominant T cell response

- Immunogenic and well tolerated<sup>1</sup>
- Showed promise in protecting animals from challenge with SARS-CoV-2 delivered directly into the lungs<sup>1</sup>

**Status: National Institute of Allergy and Infectious Diseases (NIAID) will conduct a Phase 1 clinical trial with TNX-1800**

- First vaccine candidate using Tonix's live virus recombinant pox virus (RPV) platform technology to enter clinical trials
- "Project NextGen" is an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics for COVID-19. NIAID will be conducting clinical trials to evaluate several early-stage vaccine candidates, including TNX-1800
- Phase 1 study is designed to assess safety and immunogenicity in approximately 60 healthy adult volunteers
- Upon completion of the trial, NIAID and Tonix will assess the results and determine the next steps for the development of TNX-1800

\*TNX-1800 is in the pre-IND stage of development and has not been approved for any indication

<sup>1</sup>Awasthi, M. et al. *Viruses*. 2023. 15(10):2131.

<sup>2</sup>Awasthi, M. et al. *Vaccines (Basel)*. 2023. 11(11):1682.





**TONIX**  
PHARMACEUTICALS

# INFECTIOUS DISEASE: KEY CANDIDATES



# Broad-Spectrum Antiviral Discovery Programs

## Host-directed antiviral discovery programs

- **TNX-4200: CD45 targeted therapeutics**
  - Small molecule therapeutics that reduce endogenous levels of CD45, a protein tyrosine phosphatase
  - Reduction in CD45 protects against many viruses including the Ebola virus
- **Cathepsin inhibitors**
  - Small molecule therapeutics that inhibit **essential cathepsins** which are required by viruses such as coronaviruses and filoviruses to infect cells
  - Activity as monotherapy and in combination with other antivirals

## Virus-directed antivirals discovery program

- **Viral glycan-targeted engineered biologics**
  - Bind to viral densely branched high-mannose (DBH) glycans
  - **Neutralize circulating virus** and stop the entry of the progeny virus into cells
  - Antiviral activity against a broad range of RNA viruses
  - Activity as monotherapy and in combination with other antivirals

## R&D Center (RDC): Frederick, MD

- Accelerated development of vaccines and antiviral drugs against infectious diseases
- ~48,000 square feet, BSL-2 with some areas designated BSL-3



## Tonix Awarded \$34M Contract from DoD

***Defense Threat Reduction Agency (DTRA) contract is expected to advance development of Tonix's broad-spectrum oral antiviral program, TNX-4200, for medical countermeasures***

- Other Transaction Agreement (OTA) with a potential for up to \$34 million over five years
- Objective is to develop small molecule, broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments
- Tonix's focus is to develop an orally available CD45 antagonist with broad-spectrum efficacy against a range of viral families through preclinical evaluation
  - Program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IND submission and to fund a first-in-human Phase 1 clinical study



**TONIX**  
PHARMACEUTICALS

**CNS:  
KEY DEVELOPMENT  
CANDIDATES**

# CNS-Focused Biopharma with Preclinical, Clinical and Commercial Stage Products



## TNX-102 SL for Fibromyalgia: Preparing New Drug Application (NDA)

- Granted FDA Fast Track Designation
- Two Phase 3 trials completed with statistical significance on primary endpoint
- Pre-NDA meetings with FDA completed with alignment on requirements for filing and potential approval
- NDA filing expected October 2024
- FDA decision on NDA approval expected 2025



## Marketed Products

- Zembrace® and Tosymra® indicated for the treatment of acute migraine



## Pipeline

- Phase 2 biologic cocaine antidote, FDA “Breakthrough Therapy Designation”
- Phase 1 anti-CD40L monoclonal antibody to prevent organ transplant rejection



## Strategic Partnerships

- With government institutions, world-class academic & research organizations



## Internal Capabilities

- Commercial prescription drug sales
- R&D and clinical-trial scale manufacturing

# TNX-102 SL

(Cyclobenzaprine HCl Sublingual Tablets)

---

*A unique, sublingual formulation of cyclobenzaprine designed to optimize delivery and absorption*



# Fibromyalgia is a Large, Underserved and Dissatisfied Population

- **More than 10 million U.S. adults are affected – predominantly women<sup>1,2</sup>**
  - Debilitating and life altering condition
  - Significant economic impact
- **Patients are dissatisfied, despite three FDA approved drugs<sup>3,4</sup>**
  - 85% of patients fail first-line therapy<sup>5</sup>: efficacy variability, tolerability issues especially when used long-term and lack of broad-spectrum activity
  - Typical for patients to rotate between drugs and be on multiple drugs at the same time; 79% of FM patients are on multiple therapies<sup>5</sup>
- **~2.7 million FM patients diagnosed and treated<sup>6</sup>**
  - >22 million prescriptions are issued for the treatment of fibromyalgia (on- and off-label usage) each year<sup>7,8</sup>
- **No new Rx product since 2009**
- *The treatment objective is to restore functionality and quality of life by broadly improving symptoms while avoiding significant side effects*

<sup>1</sup>American College of Rheumatology ([www.ACRPatientInfo.org](http://www.ACRPatientInfo.org) accessed May 7, 2019) – prevalence rate of 2-4% for U.S. adult population (~250 million)

<sup>2</sup>Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002; diagnosed prevalence rate was 1.1% of adult population or 50% of the prevalent population

<sup>3</sup>Robinson RL, et al. *Pain Med*. 2012 13(10):1366-76. doi: 10.1111; 85% received drug treatment

<sup>4</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

<sup>5</sup>EVERSANA primary physician research, May 2024; commissioned by Tonix

<sup>6</sup>EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>7</sup>Product sales derived from IMS MIDAS; IMS NDTI used to factor usage for fibromyalgia; data accessed April 2015.

<sup>8</sup>Market research by Frost & Sullivan, commissioned by Tonix, 2011



# About Fibromyalgia

Fibromyalgia is a **chronic pain disorder** resulting from amplified sensory and pain signaling within the CNS – now recognized as ***nociplastic pain***<sup>1-4</sup>

Fibromyalgia is a **syndrome** comprised of the ***symptoms***: chronic widespread pain, ***nonrestorative sleep***, and ***fatigue***



**Fibromyalgia is considered a chronic overlapping pain condition (COPC)<sup>5</sup>**  
**- the *only COPC with any FDA-approved drugs*<sup>6</sup>**

**Fibromyalgia is the prototypic nociplastic syndrome**

<sup>1</sup>Trouvin AP, et al. *Best Pract Res Clin Rheumatol*. 2019;33(3):101415.

<sup>2</sup>Fitzcharles MA, et al. *Lancet* 2021;397:2098-110

<sup>3</sup>Kaplan CM, et al. *Nat Rev Neurol*. 2024 20(6):347-363..

<sup>4</sup>Clauw DJ. *Ann Rheum Dis*. 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.

<sup>5</sup>Maixner W, et al. *J Pain*. 2016;17(9 Suppl):T93-T107.

<sup>6</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica®); Duloxetine (Cymbalta®); Milnacipran (Savella®)






# The Third Primary Type of Pain: Nociplastic Pain<sup>1-5</sup>

**Nociplastic syndrome includes:**

- (1) widespread pain
- (2) fatigue
- (3) sleep disturbances
- (4) cognitive dysfunction (“brain fog”)



<sup>1</sup>Trouvin AP, et al. *Best Pract Res Clin Rheumatol.* 2019;33(3):101415.

<sup>2</sup>Fitzcharles MA, et al. *Lancet* 2021;397:2098-110

<sup>3</sup>Kaplan CM, et al. *Nat Rev Neurol.* 2024 20(6):347-363..

<sup>4</sup>Clauw DJ. *Ann Rheum Dis.* 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.

<sup>5</sup>Kureshi S et al. *Healthcare (Basel)* 2024 12(3): 289.

\*ME/CFS = chronic fatigue syndrome / myalgic encephalomyelitis


\*\*PCS = post concussive syndrome.

\*\*\*IBD – irritable bowel syndrome



# Poor Sleep and Pain have Bi-directional Reinforcing Effects<sup>1</sup>

- **Poor sleep and pain form a vicious cycle in driving fibromyalgia decompensation**
  - Can't sleep → worse pain / In pain → can't sleep
  - Poor sleep and pain contribute to persistence, chronicity and severity
  - Syndrome includes symptoms of fatigue and brain fog
- **Treating sleep disturbance in fibromyalgia has the potential to break the vicious cycle**
  - Potential to remove an obstacle to recovery
  - Using the right medicine is important – some sedative/hypnotics don't work<sup>1,2</sup>




<sup>1</sup>Moldofsky H, et al. *J Rheumatol*. 1996;23:529–533.  
<sup>2</sup>Grönwald M, et al. *Clin Rheumatol*. 1993;12(2):186–191



# TNX-102 SL: Sublingual Administration and Transmucosal Delivery

- Advantages of the sublingual route
- Faster absorption provides PK that is ideal for bedtime dosing
- Bypasses “first-pass” hepatic metabolism
- Reduced metabolism of parent CBP to active metabolite norcyclobenzaprine (nCBP)





# Fibromyalgia Program Status

## TNX-102 SL

Cyclobenzaprine Protectic®  
Sublingual Tablets

Fibromyalgia

**Statistically Significant 2<sup>nd</sup> Phase 3 Topline Results  
Reported 4Q'23**

- First pivotal Phase 3 study (*RELIEF*) reported – December 2020<sup>1</sup>
- Second Phase 3 study (*RALLY*) missed primary endpoint – July 2021
- Confirmatory pivotal Phase 3 study (*RESILIENT*) reported – December 2023
- Pre-NDA meetings with FDA completed with alignment on requirements for filing and potential approval
- Granted FDA Fast Track Designation

**Next Steps:**

- NDA filing expected **October '24**
- FDA decision on NDA approval expected **2025**


<sup>1</sup>Lederman S, et al. *Arthritis Care Res (Hoboken)*. 2023 Nov;75(11):2359-2368. doi: 10.1002.

# RESILIENT Primary Outcome Measure

## Reduction in Widespread Pain



### Weekly Average of Daily Diary NRS Ratings of Average Pain Over Prior 24 Hours



Week 14 LS mean (SE) change from baseline for TNX-102 SL -1.82 (0.12) and for placebo -1.16 (0.12); LSMD from placebo -0.65 (0.16); **p=0.00005#**

#Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction. Abbreviations: LS, least squares; LSMD, least squares mean difference; NRS, numerical rating scale; SE, standard error

# RESILIENT Summary of Endpoints



Endpoint	P-value	Effect Size (ES)
<b>Primary Endpoint</b>		
Daily Diary Pain ratings	$p = 0.00005^{**}$	ES = 0.38
<b>Key Secondary Endpoints*</b>		
Patient Global Impression of Change (PGIC), responders	$p = 0.00013^{**}$	--
Fibromyalgia Impact Questionnaire – Symptoms domain	$p = 0.000002^{**}$	ES = 0.44
Fibromyalgia Impact Questionnaire – Function domain	$p = 0.001^{**}$	ES = 0.30
PROMIS Sleep Disturbance instrument	$p = 0.0000001^{**}$	ES = 0.50
PROMIS Fatigue instrument	$p = 0.00009^{**}$	ES = 0.37
Diary Sleep Quality ratings	$p = 0.0007^{**}$	ES = 0.32

\*In order of statistical serial gate-keeping hierarchy (or, “waterfall”) to control overall Type 1 error

\*\*Statistical significance met



# RESILIENT – Cognitive Dysfunction or “Brain Fog”

## Brain Fog assessed by the FIQ-R<sup>1</sup> item on memory

- Patients rated their level of memory problems
- 11-pt scale going from “Good Memory” to “Very Poor Memory”
- Prespecified endpoint, but not in the “waterfall” with the key secondary endpoints
  
- TNX-102 SL patients vs PBO change from baseline LS mean (SE) difference of  $-0.8$  ( $0.23$ )
- $p = 0.001$  (not corrected for multiple comparisons)
- Cohen’s  $d$  effect size =  $0.31$



<sup>1</sup>FIQ-R = Fibromyalgia Impact Questionnaire - Revised



# TNX-102 SL Showed Broad-Spectrum Activity and was Well Tolerated

		Lyrica®	Cymbalta® Savella®	TNX-102 SL
<b>Activity</b>	Pain	<b>YES</b>	<b>YES</b>	<b>YES</b>
	Sleep	<b>YES</b>	-	<b>YES</b>
	Fatigue	-	<b>YES</b>	<b>YES</b>
<b>Systemic Tolerability Issues</b>	Insomnia	-	<b>+</b>	-
	Fatigue	<b>+</b>	-	-
	Weight	<b>+</b>	-	-
	Blood Pressure	-	<b>+</b>	-
	Sexual function	-	<b>+</b>	-
	GI issues	-	<b>+</b>	-

- TNX-102 SL showed activity in all three measures of pain, sleep, and fatigue
- TNX-102 SL is not associated with any of the commonly reported side effects





## Tolerability

- **Completion Rate (safety population): TNX-102 SL: 81.0% and Placebo: 79.2%**
- **No new safety signals observed**
- **Only systemic adverse events (AEs) at rate  $\geq 3.0\%$  (TNX-102 SL v. Placebo)**
  - COVID-19 (4.3% v. 3.1%), somnolence (3.0% v. 1.3%), and headache (3.0% v. 1.8%)
- **As previously observed TNX-102 SL associated with administration site reactions**
  - Hypoaesthesia oral (23.8% v. 0.4%), product taste abnormal (11.7% v. 0.9%), paraesthesia oral (6.9% v. 0.9%), and tongue discomfort (6.9% v. 0%)
- **No effect on weight or blood pressure (BP)**
  - Weight: Week 14 change from baseline for TNX-102 SL of +0.04 lbs.; and for Placebo of +0.44 lbs.
  - Systolic BP: Week 14 change from baseline for TNX-102 SL of +0.7 mmHg; and for Placebo of +0.5 mmHg
  - Diastolic BP: Week 14 change from baseline for TNX-102 SL of +1.1 mmHg; and for Placebo of +0.2 mmHg
- **No sexual dysfunction AEs and improved female sexual functioning**
  - No reported AEs of any type of sexual dysfunction
  - Improvement in female sexual function using Changes in Sexual Functioning Questionnaire ( $p=0.010$ )



## Treatment-Emergent Adverse Events (TEAEs) at Rate of $\geq 3\%$ in Either Treatment Group

System Organ Class Preferred Term	TNX-102 SL N=231	Placebo N=226	Total* N=457
<b>Systemic Adverse Events</b>			
COVID-19	10 (4.3%)	7 (3.1%)	17 (3.7%)
Somnolence	7 (3.0%)	3 (1.3%)	10 (2.2%)
Headache	7 (3.0%)	4 (1.8%)	11 (2.4%)
<b>Oral Cavity Adverse Events</b>			
Hypoaesthesia oral	55 (23.8%)	1 (0.4%)	56 (12.3%)
Product taste abnormal	27 (11.7%)	2 (0.9%)	29 (6.3%)
Paraesthesia oral	16 (6.9%)	2 (0.9%)	18 (3.9%)
Tongue discomfort	16 (6.9%)	0 (0.0%)	16 (3.5%)

\*Safety Population



# ~50% of U.S. Fibromyalgia Patients are on Medicare: Prescription Coverage in Medicare Stands to Benefit from Changes in IRA


## Approximately 50% of fibromyalgia patients are on Medicare

- EVERSANA analysis of claims database consisting of 2.2M patients, for which 1.2M claims were submitted throughout March 2002-March 2023<sup>1</sup>

## Beneficial Changes in 2025 to Medicare Part D through Inflation Reduction Act (IRA)<sup>2</sup>

- Medicare prescription payment plan to offer enrollees the option to pay out-of-pocket prescription drug costs in the form of capped monthly installment payments instead of all at once at the pharmacy
- Annual out-of-pocket costs will be capped at \$2,000 in year 2025
- Will replace the existing Coverage Gap Discount Program, which sunsets as of January 1, 2025

## Fibromyalgia Patients by Coverage<sup>1</sup>




<sup>1</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>2</sup> Source: [Final CY 2025 Part D Redesign Program Instructions Fact Sheet | CMS](#)


# Prescribers Interviewed are Broadly Dissatisfied with Available Fibromyalgia Medications: Results of Primary Research<sup>1</sup>



Perspectives on FM Therapies from Prescribers Interviewed		
Drug	Positives	Negatives
<b>Duloxetine</b> ( <i>Cymbalta, generic</i> )	<ul style="list-style-type: none"> <li>Relatively high efficacy (compared to alternatives)</li> <li>Can be titrated slowly from 20mg to 120mg</li> </ul>	<ul style="list-style-type: none"> <li>Tolerability issues: worsening depression, insomnia</li> <li>Seldom used as a monotherapy; often requires adjunct</li> </ul>
<b>Pregabalin</b> ( <i>Lyrica, generic</i> )	<ul style="list-style-type: none"> <li>Relatively high efficacy (compared to alternatives)</li> <li>Can often be safely combined with other medications</li> </ul>	<ul style="list-style-type: none"> <li>Suboptimal for long-term use (e.g., weight gain)</li> <li>Schedule V status makes some HCPs more cautious to Rx</li> </ul>
<b>Savella</b> ( <i>milnacipran</i> )	<ul style="list-style-type: none"> <li>Offers another option if patient fails Cymbalta or Lyrica</li> </ul>	<ul style="list-style-type: none"> <li>Subpar efficacy does not counterbalance tolerability issues</li> <li>High cost and access constraints (~\$50/month)</li> </ul>
<b>Cyclobenzaprine</b> ( <i>Flexeril, generic; oral formulation, off-label</i> )	<ul style="list-style-type: none"> <li>Active for initiating and sustaining sleep; can be titrated up</li> <li>Active for pain driven by stiffness and muscle spasms</li> </ul>	<ul style="list-style-type: none"> <li>Mixed perspectives on pain benefit independent of sleep</li> <li>Suboptimal long-term results as efficacy wanes</li> </ul>



**85% of patients (avg) fail first line therapy**



**79% of FM patients (avg) are on multiple therapies**

<sup>1</sup> EVERSANA primary physician research, May 2024; commissioned by Tonix

# Opportunity for a New, Unique Fibromyalgia Treatment Option: Results of Primary Research from EVERSANA<sup>1,2</sup>



## FM Landscape

- Prescribers indicate a **very high unmet need** in FM (ranked  $\geq 4.0$  on a 5-point scale)
- Prescribers report there is **no standard of care in FM**, employ an **individualized approach** based on symptomology
- No new treatments approved since 2009
- Prescribers report minimal promotional activities by any pharmaceutical company
- Highly concentrated prescriber base with 50% of patients treated by ~16k physicians



## Physician Primary Market Research

- **Physicians reacted positively to the efficacy and safety profile of TNX-102 SL (based on Phase 3 Study results)**
- Median interest = 4.0 on a 5-point scale
- Driving attributes included **strong efficacy, safety and tolerability**
- Unique & differentiating efficacy features included improvements in **sleep and fatigue**



## Anticipated Use

- **Physicians indicated intended use in 40% of their FM patients**
- Majority of respondents indicated TNX-102 SL would be their first choice, if accessible
- Physicians surveyed indicated they are well-equipped to deal with access restrictions including prior authorizations and step-edits


<sup>1</sup> EVERSANA primary physician research, May 2024; commissioned by Tonix

<sup>2</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix



# Many Fibromyalgia Patients are Prescribed Off-Label Drugs; ~53% FM Patients Prescribed Opioids Off-Label<sup>1,2</sup>

% FM Patients (after index<sup>3</sup> date)



<sup>1</sup> 2022-2023

<sup>2</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>3</sup> Index date refers to date when ICD10 code was entered into database



# Planning for TNX-102 SL Launch and Marketing

Several companies that successfully developed CNS drugs have launched them

- Big Pharma wants the commercial launch de-risked before acquisition (e.g., Nurtec®)

Company		Mkt Cap <sup>1</sup>	Product	Indication	FDA Approval	Exit
Axsome	AXSM	\$3.5 B	Auvelity®	Depression	8/2022	
Biohaven	BHVN	\$3.0 B	Nurtec®	Migraine	2/2020	Sold to PFE for \$12 B in Oct 2022
IntraCellular	ITCI	\$7.2 B	Caplyta®	Schizophrenia	12/2019	
Supernus	SUPN	\$1.4 B	Oxtella-XR®	Seizures	1/2019	
Neurocrine	NBIX	\$13.6 B	Ingrezza®	Tardive Dyskinesia	4/2017	
Acadia	ACAD	\$2.5 B	Nuplazid®	Parkinson's psychosis	4/2016	

To prepare for the launch of TNX-102 SL, Tonix acquired two marketed Rx drugs: Zembrace® and Tosymra®

- Both are indicated for the acute treatment of migraine

<sup>1</sup>Accessed June 7, 2024



# Two Marketed Proprietary Migraine Drugs Non-oral Formulations of Sumatriptan

## Zembrace® SymTouch® (sumatriptan injection) 3 mg<sup>1</sup>



- Each indicated for the **treatment of acute migraine with or without aura in adults**
- Sumatriptan remains the acute migraine ‘gold standard’ treatment for many patients and continues to represent the largest segment of the market in terms of unit sales<sup>3</sup>
- Each may provide migraine **pain relief in as few as 10 minutes** for some patients<sup>1,2,4,5</sup>
- Patents to 2036 (Zembrace) and 2031 (Tosymra)

## Tosymra® (sumatriptan nasal spray) 10 mg<sup>2</sup>



### Acquired from Upsher-Smith Laboratories which has managed care contracts covering ~200 M lives

- Contract includes a transition period during which Tonix expects to secure its own contracts

### Tonix Medicines Commercial Subsidiary

- Complete commercialization capability
  - Manage supply chain and contract manufacturer
  - Distribution
  - Trade, Managed Care & Government contracting
- Team of professionals including Sales & Marketing personnel

<sup>1</sup>Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021 - For more information, talk to your provider and read the [Patient Information and Instructions for Use](#). – Important Safety Information is provided in the appendix

<sup>2</sup>Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: Feb 2021. For more information, talk to your provider and read the [Patient Information and Instructions for Use](#). – Important Safety Information is provided in the appendix

<sup>3</sup>Tonix Medicines, Inc.; Data On File, 2023

<sup>4</sup>Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.

<sup>5</sup>Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines, Inc. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc.





# CNS-Focused Biopharma with Preclinical, Clinical and Commercial Stage Products



## TNX-102 SL for Fibromyalgia: Preparing New Drug Application (NDA)

- Granted FDA Fast Track Designation
- Two Phase 3 trials completed with statistical significance on primary endpoint
- Pre-NDA meetings with FDA completed with alignment on requirements for filing and potential approval
- NDA filing expected October 2024
- FDA decision on NDA approval expected 2025



## Marketed Products

- Zembrace® and Tosymra® indicated for the treatment of acute migraine



## Pipeline

- Phase 2 biologic cocaine antidote, FDA “Breakthrough Therapy Designation”
- Phase 1 anti-CD40L monoclonal antibody to prevent organ transplant rejection



## Strategic Partnerships

- With government institutions, world-class academic & research organizations



## Internal Capabilities

- Commercial prescription drug sales
- R&D and clinical-trial scale manufacturing



# Acute Stress Reaction (ASR) / Acute Stress Disorder (ASD)

*ASR/ASD are acute stress conditions resulting from trauma which can affect both civilian and military populations.*

## Large unmet need:

- According to National Center for PTSD, about 60% of men and 50% of women in the US are exposed least one traumatic experience in their lives<sup>1</sup>
- In the US alone, one-third of emergency department visits (40-50 million patients per year) are for evaluation after trauma exposures<sup>2</sup>

## Current standard of care:

- No medications are currently available at or near the point of care to treat patients suffering from acute traumatic events and support long-term health

<sup>1</sup>National Center for PTSD. How Common is PTSD in Adults? [https://www.ptsd.va.gov/understand/common/common\\_adults.asp](https://www.ptsd.va.gov/understand/common/common_adults.asp)

<sup>2</sup>Wisco et al. *J Clin Psychiatry*. 2014.75(12):1338-46



# TNX-102 SL for ASR/ASD: Program Status

**Status:** Expect to start investigator-initiated Phase 2 in 3Q 2024; received IND clearance from FDA

## Investigator-initiated Phase 2 Trial Funded by DoD grant to University of North Carolina (UNC)

- UNC Institute for Trauma Recovery awarded a \$3M grant from the Department of Defense (DoD)
- OASIS trial will build upon infrastructure developed through the UNC-led, \$40M AURORA initiative
  - AURORA study is a major national research initiative to improve the understanding, prevention, and recovery of individuals who have experienced a traumatic event
  - Supported in part by funding from the National Institutes of Health (NIH) and the health care arm of Google’s parent company Alphabet
- Opportunity to investigate the correlation between motor vehicle collisions and the emergence of ASD and PTSD
- Supported by multiple clinical trials:
  - Phase 2 trial in military-related PTSD (AtEase or NCT02277704)
  - Phase 3 trial in military-related PTSD (HONOR or NCT03062540)
  - Phase 3 trial in primarily civilian PTSD (RECOVERY or NCT03841773)
- In each of these studies, early and sustained improvements in sleep were associated with TNX-102 SL treatment by the PROMIS sleep disturbance (SD) scale and the Clinician Administered PTSD Scale (CAPS-5) “sleep disturbance” item.

***Together these studies provide preliminary evidence that TNX-102 SL is well-tolerated and may promote recovery from PTSD via a pharmacodynamic facilitation of sleep-dependent emotional memory processing***



## Significant Overlap between Fibromyalgia and Long-COVID

National Institutes of Health (NIH)-sponsored RECOVER study found many Long COVID patients suffer from pain at multiple sites<sup>1</sup>

- Suggests that many Long-COVID patients may meet the diagnostic criteria for fibromyalgia

Tonix has previously presented its analysis of real-world evidence from the TriNetX claims database suggesting that ***over 40% of Long COVID patients present with a constellation of symptoms that overlap with fibromyalgia***<sup>2,3</sup>

<sup>1</sup>Thaweethai T, et al. *JAMA*. 2023 329(22):1934-1946.

<sup>2</sup>Feb 22, 2023 Tonix Pharmaceuticals Press Release. URL: <https://ir.tonixpharma.com/news-events/press-releases/detail/1369/tonix-pharmaceuticals-describes-emerging-research-on-the>

<sup>3</sup>September 21, 2022, Tonix Pharmaceuticals Poster at the IASP, "Retrospective observational database study of patients with Long COVID with multi-site pain, fatigue and insomnia".

URL: [www.tonixpharma.com/wp-content/uploads/2022/09/Retrospective-Observational-Database-Study-of-Patients-with-Long-COVID-with-Multi-Site-Pain-Fatigue-and-Insomnia\\_A-Real-World-Analysis-of-Symptomatology-and-Opioid-Use.pdf](http://www.tonixpharma.com/wp-content/uploads/2022/09/Retrospective-Observational-Database-Study-of-Patients-with-Long-COVID-with-Multi-Site-Pain-Fatigue-and-Insomnia_A-Real-World-Analysis-of-Symptomatology-and-Opioid-Use.pdf)



## NASEM Definition of Long-COVID

- In June 2024, the US National Academies of Sciences, Engineering and Medicine (NASEM) described **fibromyalgia as a ‘diagnosable condition’ in people suffering from Long COVID<sup>1</sup>**
- This definition provides guidance to government, healthcare professionals and industry that fibromyalgia can arise after infection with the SARS-CoV-2 virus and can be diagnosed in Long COVID patients

***Fibromyalgia prevalence prior to COVID-19 pandemic: >10M adults in the US<sup>2</sup>***

***Long-COVID prevalence: 5.3% or ~14M adults in the US<sup>3</sup>***

**Tonix believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL as compared to market estimates from before the COVID-19 pandemic**

<sup>1</sup>U.S. National Academies of Sciences, Engineering, and Medicine. 2024. *A Long COVID Definition: A chronic, systemic disease state with profound consequences*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/27768>. <http://www.nationalacademies.org/long-covid-definition>.

<sup>2</sup>Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002

<sup>3</sup>National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey, 2022–2024. Long COVID. Generated interactively: July 22, 2024 from <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>



# TNX-102 SL: Patents and Patent Applications

- **U.S. Composition:\***
  - A 75:25 cyclobenzaprine HCl - mannitol eutectic (dependent claims add a basifying agent).
    - 5 US Patents (Expire March 2034)
    - 1 Pending US Application (Would expire March 2034)
  - A composition of a cyclobenzaprine HCl and a basifying agent suitable for sublingual absorption.
    - 1 Pending US Application (Would expire June 2033)
- **U.S. Methods of Use\* (Specific Indications):**
  - Fibromyalgia
    - Pain, Sleep Disturbance, Fatigue
      - 1 Pending US Application (Would expire December 2041)
    - Early Onset Response and Tolerability/Side Effect Profile
      - 2 Pending US Provisional Applications (Would expire December 2044)
    - Depressive Symptoms
      - 1 Pending US Application (Would expire March 2032)
  - Sexual Dysfunction
    - 1 Pending US Application (Would expire April 2041)
  - PASC
    - 1 Pending US Application (Would expire June 2043)
  - PTSD
    - 1 US Patent (Expires November 2030)
    - 1 Pending US Application (Expires August 2039)
  - Agitation (Dementia)
    - 1 US Patent (Expires December 2038)
  - Alcohol Use Disorder
    - 1 Pending US Application (Would expire November 2041)
  - Acute Stress Reaction/Acute Stress Disorder
    - 1 Pending US Provisional Application (Would expire January 2045)
- **Foreign Filings**
  - Corresponding foreign patents have been filed and some have issued:
    - Composition (40 patents and 14 pending applications)
    - Methods of Use (11 patents, 1 allowed application, 75 pending applications)

\*US Patents: Issued: US Patent Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321. Pending: US Patent Application Nos. 13/918,692; 18/385,468; 13/412,571; 18/265,525; 63/612,352; 63/618,892; 18/037,815; 17/226,058; 18/212,500; 17/269,106.

# Additional Programs and Pipeline Strategy

---

## Focusing on government and academic collaborations

- Validates Tonix's scientific expertise and technology
- Reduces internal spend
- Increases number of trials
- Potentially speeds time to market
- Grants, contracts, cost-sharing or "in-kind" arrangements

# TNX-1500: Next Generation anti-CD40L mAb

Re-engineered to better modulate the binding of FcγR and mitigate risk of thrombosis

Clinical Stage of Phase 1 study completed


## Key Differentiators

Expected to deliver efficacy without compromising safety

**First Generation:** Development halted due to thromboembolic (TE) complications—blood clots—traced to Fc gamma receptor (FcγR)

**Second Generation:** Eliminated the FcγR TE complication but potency and half life was reduced, limiting utility

**Third Generation (TNX-1500):** Re-engineered to better modulate the binding of FcγR.



Contains the full ruplizumab Fab and the engineered Fc region that modulates FcγR-binding, while preserving FcRn function



# External Partnerships

Government partners providing direct funding, cost sharing or in-kind support include:

- **National Institutes of Health (NIH)**
- **National Institute of Allergy and Infectious Disease (NIAID)**
  - TNX-1800 selected for Project NextGen
- National Institute on Drug Abuse (NIDA)
  - TNX-1300 for cocaine intoxication; Phase 2 study funding
- **Department of Defense (DoD)**
  - TNX-4200 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments
  - TNX-102 SL for ASD; investigator-initiated Phase 2 study funding

Academic partners sponsoring clinical trials of Tonix's investigational drug products include:

- Massachusetts General Hospital (MGH)
- University of Washington
- University of North Carolina

# Key Partnerships

## TNX-1500: ALLOGRAFT REJECTION



## TNX-102 SL: ACUTE STRESS DISORDER



U.S. Department of Defense



THE UNIVERSITY  
of NORTH CAROLINA  
at CHAPEL HILL

## TNX-2900: PRADER-WILLI SYNDROME



## TNX-1300: COCAINE INTOXICATION



National Institute  
on Drug Abuse



## TNX-1800: COVID-19 VACCINE



National Institutes  
of Health



National Institute of  
Allergy and  
Infectious Diseases

## TNX-4200: BROAD-SPECTRUM ANTIVIRAL



U.S. Department of Defense





**TONIX**  
PHARMACEUTICALS

**TEAM,  
NETWORK, &  
UPCOMING  
MILESTONES**



# Management Team



**Seth Lederman, MD**  
Co-Founder, CEO & Chairman



**Gregory Sullivan, MD**  
Chief Medical Officer



**Bradley Saenger, CPA**  
Chief Financial Officer



**Jessica Morris**  
Chief Operating Officer



# Milestones: Recently Completed and Upcoming

## TNX-102 SL for the Management of Fibromyalgia Milestones

- 4<sup>th</sup> Quarter 2023 Statistically significant topline results of Phase 3 RESILIENT study – 2<sup>nd</sup> statistically significant Phase 2 trial
- 2<sup>nd</sup> Quarter 2024 Type B CMC and clinical pre-NDA meetings with FDA
- 3<sup>rd</sup> Quarter 2024 FDA Fast Track Designation granted by FDA
- October 2024 Submit NDA to FDA for TNX-102 SL for fibromyalgia

## Other Key Program Milestones

- 3<sup>rd</sup> Quarter 2024 U.S. DoD / DTRA Awarded \$34 M contract (over 5 years) for broad spectrum antiviral development (TNX-4200)
- 3<sup>rd</sup> Quarter 2024 Initiate Phase 2 study of TNX-1300 for the treatment of cocaine intoxication
- 3<sup>rd</sup> Quarter 2024 Initiate Phase 2 study of TNX-102 SL for acute stress disorder

The image is a composite graphic. The left side features a dark blue background with a large, semi-transparent molecular structure graphic consisting of several spheres connected by lines. The right side shows a photograph of a family of four (a mother, a father, and two young children) walking through a grassy field. The mother is carrying one child, and the father is carrying another. They are all smiling and looking towards each other. The background of the photo is a soft-focus green field. The overall design is split diagonally from the top-left to the bottom-right.

**THANK YOU**



## Zembrace® Important Safety Information (1 of 2)

**Zembrace SymTouch (Zembrace) can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:**

- Discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back; severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw; pain or discomfort in your arms, back, neck, jaw or stomach; shortness of breath with or without chest discomfort; breaking out in a cold sweat; nausea or vomiting; feeling lightheaded

Zembrace is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace if you have:

- History of heart problems; narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease); uncontrolled high blood pressure; hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
- Had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation; severe liver problems; taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, dihydroergotamine; are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
- An allergy to sumatriptan or any of the components of Zembrace

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



## Zembrace® Important Safety Information (2 of 2)

### Zembrace may cause serious side effects including:

- Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet; increased blood pressure including a sudden severe increase even if you have no history of high blood pressure; medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
- Serotonin syndrome, a rare but serious problem that can happen in people using Zembrace, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
- Hives (itchy bumps); swelling of your tongue, mouth, or throat
- Seizures even in people who have never had seizures before

The most common side effects of Zembrace include: pain and redness at injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired.

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace. For more information, ask your provider.

This is the most important information to know about Zembrace but is not comprehensive. For more information, talk to your provider and read the [Patient Information](#) and [Instructions for Use](#). You can also visit [www.upsher-smith.com](http://www.upsher-smith.com) or call 1-888-650-3789. For full Prescribing Information, visit: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5b104f-2b9e-416e-92fb-ef1bd8aea867d>

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Zembrace is a prescription medicine used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace is not used to prevent migraines. It is not known if it is safe and effective in children under 18 years of age.





## Tosymra® Important Safety Information (1 of 2)

**Tosymra® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop Tosymra and get emergency medical help if you have any signs of heart attack:**

- Discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back; severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw; pain or discomfort in your arms, back, neck, jaw, or stomach; shortness of breath with or without chest discomfort; breaking out in a cold sweat; nausea or vomiting; feeling lightheaded

Tosymra is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem.

Do not use Tosymra if you have:

- History of heart problems; narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease); uncontrolled high blood pressure; severe liver problems; hemiplegic or basilar migraines. If you are not sure if you have these, ask your healthcare provider.
- Had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation; taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider if you are not sure if your medicine is listed above
- are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure
- An allergy to sumatriptan or any ingredient in Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



## Tosymra® Important Safety Information (2 of 2)

### Tosymra may cause serious side effects including:

- Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramping and pain in your legs or hips, feeling of heaviness or tightness in your leg muscles, burning or aching pain in your feet or toes while resting, numbness, tingling, or weakness in your legs, cold feeling or color changes in one or both legs or feet; increased blood pressure including a sudden severe increase even if you have no history of high blood pressure; medication overuse headaches from using migraine medicine for 10 or more days each month. **If your headaches get worse, call your provider.**
- Serotonin syndrome, a rare but serious problem that can happen in people using Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. **Call your provider right away if you have:** mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
- Seizures even in people who have never had seizures before

**The most common side effects of Tosymra include:** tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation.

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Tosymra. For more information, ask your provider.

This is the most important information to know about Tosymra but is not comprehensive. For more information, talk to your provider and read the [Patient Information and Instructions for Use](#). You can also visit [www.upsher-smith.com](http://www.upsher-smith.com) or call 1-888-650-3789. For full Prescribing Information, visit: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=015a5cf9-f246-48bc-b91e-cd730a53d8aa>

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Tosymra is a prescription medicine used to treat acute migraine headaches with or without aura in adults.

Tosymra is not used to treat other types of headaches such as hemiplegic or basilar migraines or cluster headaches.

Tosymra is not used to prevent migraines. It is not known if Tosymra is safe and effective in children under 18 years of age.